Sarcoma are the type of cancer that develops from tissues such as nerves, muscles, fats, blood vessels and deep skin tissues. It occurs in the blood vessels, muscles, and tissues that protects, supports and surround the organs. It is not categorized as tumor, but a life-threatening disease when the cancer has spread to the other body parts. Currently, there are around 50 different types of soft tissue sarcoma, few of them are Adult fibrosarcoma, Angiosarcoma, Clear cell sarcoma, Alveolar soft-part sarcoma, Kaposi sarcoma, Malignant mesenchymoma, and Rhabdomyosarcoma among others. Few of the drus used for the treatment of soft tissue sarcoma includes Bevacizumab (Avastin®), Doxorubicin (Adriamycin), Sunitinib (Sutent®), Sirolimus (Rapamune®), and Trabectedin (Yondelis®) among others.
Soft tissue sarcoma can be diagnosed with some physical examination such as X-ray imaging, CT scanning, MRI, ultrasound, PET scan and a biopsy. Physical examination with other test are used to diagnose the stage of soft tissue sarcoma, which is important to plan the treatment method. According to the American Cancer Society, around 12,390 new patients with soft tissue sarcoma will be diagnose by the end of 2017 and around 55% of the cases are reported to males. Moreover, around 4,990 American are expected to die due to soft tissue sarcoma in coming year.
Increasing cases of soft tissue sarcoma and different types of cancer are expected to boost the growth for soft tissue sarcoma market. Few of the major driving factors includes increasing research and development on biological and targeted drug therapies for the cancer treatment along with the expiration of patents. The increasing spending on healthcare per capita for quality patient care and various advanced treatments also boost the growth of the global soft tissue sarcoma treatment market. In addition, increasing focus on personalized medicine along with the huge investment for anti-cancer treatment research is likely to unveil the new paths for soft tissue sarcoma treatment market in the near future.
However, the side effects of cost associated with soft tissue sarcoma treatment may hamper the growth of the global soft tissue sarcoma treatment market. Similarly, high cost of chemotherapy and radiation therapy, stringent government regulation, and high failure rate of clinical trials might hamper the market growth to some extent.
Based on treatment type, the global soft tissue sarcoma treatment market has been segmented into chemotherapy, targeted therapy, anti-angiogenesis drugs, radiation therapy, and surgery. Surgery and chemotherapy segment is expected to dominate the global soft tissue sarcoma market. Hospitals are expected to contribute highest share in the global soft tissue sarcoma treatment market over the forecast period due to large number of patients receiving treatment at hospitals for soft tissue sarcoma and related cancer.
Based on end user, the global soft tissue sarcoma treatment market has been segmented into hospitals, oncology centers, and long term care centers. Hospitals are expected to contribute highest share in the global soft tissue sarcoma treatment market over the forecast period due to large number of patients receiving treatment at hospitals for soft tissue sarcoma and related cancer.
On the basis of regional presence, global soft tissue sarcoma treatment market is segmented into five key regions viz. North America, Latin America, Europe, Asia Pacific, and Middle East & Africa. North America is expected to lead the global market due to high incidence rate of cancer and soft tissue sarcoma, while Europe is expected to hold second largest market share in the global market. Market in Asia-Pacific region is expected to witness significant growth owing to increasing case of cancer and growing awareness regarding advanced cancer treatments. In addition, increasing healthcare expenditure related to cancer and associated disease is expected to boost the market growth in near future.
A Sample of this Report is Available Upon Request @ http://www.persistencemarketresearch.com/samples/15625
Some of the players operating in global soft tissue sarcoma treatment market are Eli Lilly and Company, Genentech USA, Pfizer, Inc., Johnson & Johnson Services, Inc. GlaxoSmithKline, Bristol-Myers Squibb, Teva Pharmaceuticals, Hoffmann-La Roche Ltd, and Celgene Corporation among others.
Request to View Tables of Content @ http://www.persistencemarketresearch.com/toc/15625